KLRA — Kailera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2096997 ·
Last close
$11.22
Market Cap
$1.45B
52W High
$28.23
52W Low
$11.10
ADV30
1,058,890
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -121,373,000 | -111,307,000 | 1,211,416,000 | 130,301,000 | 92,952,000 |
| Mar 2026 | 0 | — | -84,660,000 | -78,865,000 | 624,756,000 | 111,826,000 | 1,056,844,000 |
| Jun 2025 | 0 | — | -30,651,000 | -28,947,000 | — | — | — |
| Mar 2025 | 0 | — | -20,458,000 | -17,983,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,511,000
Investing CF
$-31,591,000
Financing CF
$-2,980,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-447,533,000
Inventory
—
Receivables
$3,208,000
ST Investments
$407,348,000
EBIT TTM
$-105,118,000
Pretax Income TTM
$-96,848,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -158,340,000 | -148,955,000 | 692,294,000 | 1,048,752,000 | -356,458,000 | -120,210,000 |
| Dec 2024 | — | — | — | 178,445,000 | 397,217,000 | -218,772,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OMER | OMEROS CORP | $1.45B | $20.08 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.43B | $14.50 | — |
| INVA | Innoviva, Inc. | $1.50B | $20.74 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | $28.45 | — |
| ANAB | ANAPTYSBIO, INC | $1.51B | $51.00 | — |
News headlines (Yahoo Finance, 1h cache)
Kailera Therapeutics to Participate in September Investor Conferences
2026-09-16 11:00 · Yahoo
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
2026-09-15 04:16 · Yahoo
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2026-08-18 14:10 · Yahoo
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
2026-08-17 13:10 · Yahoo
2 GLP-1 Stocks That Could Double Your Money by 2031
2026-08-16 20:20 · Yahoo
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-12 20:05 · Yahoo
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Kailera weight loss pill trial results: Nausea sinks stock
2026-07-08 14:10 · Yahoo
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
2026-07-07 20:09 · Yahoo
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
2026-07-07 18:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.